Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCR001 in Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis
NCT05098145Phase 2Withdrawn
- Sponsor
- Talaris Therapeutics
- Start
- Nov 2021
- Primary completion
- Nov 2026
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs
- Countries
- 1
01
Overview
A Phase 2 trial of FCR001 in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Talaris Therapeutics. Planned start Nov 2021; status: withdrawn.
02
Drugs
FCR001
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT05098145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098145.